CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Sitagliptin Phosphatedrug
Likely dose
Sitagliptin Phosphate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00795275
NCT00795275N/ACompleted
CompareCT.gov

Exploring the Incretin Effect in People With IFG

University of Colorado, Denver·interventional·Posted Nov 21, 2008·Updated Apr 5, 2021

In Brief

A clinical study evaluating Sitagliptin Phosphate for Obesity. Completed, enrolled 26 participants across 1 site.

Detailed Summary

Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people with impaired fasting glucose (IFG) was the objective of the current study. The investigators hypothesized that defects in GLP-1 may explain the inappropriate basal EGP and diminished insulin secretion in IFG, and, furthermore, that by increasing circulating GLP-1 levels (using a new medicine called "sitagliptin") the investigators could reverse these defects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 21, 2008
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.6 years ago

Interventions

Sitagliptin Phosphatedrug

Januvia 100 mg po qd x 28 days for all subjects after baseline measures made